Cell Growth & Differentiation, Vol 1, Issue 8 367-374, Copyright © 1990 by American Association of Cancer Research

ARTICLES

Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta

CL Arteaga, RJ Coffey Jr, TC Dugger, CM McCutchen, HL Moses and RM Lyons
Department of Medicine, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232.

Exogenous TGF beta inhibits the proliferation of human breast cancer cells in vitro. These cells synthesize and secrete TGF beta into their medium predominantly in a latent form. With neutralizing antibodies against native, biologically active TGF beta (278ab and 282ab), we have examined whether HS578T and MDA-231 breast cancer cells utilize their endogenous TGF beta for growth regulation. Low levels of TGF beta activity were detectable in conditioned medium from confluent monolayers of both cell lines in the absence of acid or protease treatment as measured by radioreceptor assay. When added to subconfluent monolayers of the respective cell line, this untreated conditioned medium inhibited DNA synthesis and cell proliferation. This inhibition was blocked by anti-TGF beta antibodies, whereas nonimmune rabbit IgG had no effect. Similar to exogenous TGF beta 1, this conditioned medium induced a dose-dependent increase in steady-state TGF beta 1 mRNA levels when added to subconfluent HS578T cells; this increase was blocked by the 278ab. Consistent with the above, preincubation of either cell line with anti-TGF beta antibodies increased subsequent specific binding of 125I-TGF beta to cell surface receptors without changing binding affinity. Addition of 278ab to quiescent HS578T or MDA-231 cells induced a dose-dependent increase in [3H]thymidine incorporation. Both antibodies stimulated cell proliferation in serum-free medium and anchorage-independent growth of both cell lines. Finally, incubation of HS578T cells with 278ab under serum-free conditions decreased the basal level of TGF beta 1 message expression. These data indicate that cultured human breast cancer cells utilize endogenously produced TGF beta as an autocrine negative growth regulator.

This article has been cited by other articles:

				J. Wang, L. Yang, J. Yang, K. Kuropatwinski, W. Wang, X.-Q. Liu, J. Hauser, and M. G. Brattain Transforming Growth Factor {beta} Induces Apoptosis through Repressing the Phosphoinositide 3-Kinase/AKT/Survivin Pathway in Colon Cancer Cells Cancer Res., May 1, 2008; 68(9): 3152 - 3160. [Abstract] [Full Text] [PDF]

				J. Wang, N. Sergina, T. C. Ko, J. Gong, and M. G. Brattain Autocrine and Exogenous Transforming Growth Factor {beta} Control Cell Cycle Inhibition through Pathways with Different Sensitivity J. Biol. Chem., September 17, 2004; 279(38): 40237 - 40244. [Abstract] [Full Text] [PDF]

				J. Qing, C. Liu, L. Choy, R.-Y. Wu, J. S. Pagano, and R. Derynck Transforming Growth Factor {beta}/Smad3 Signaling Regulates IRF-7 Function and Transcriptional Activation of the Beta Interferon Promoter Mol. Cell. Biol., February 1, 2004; 24(3): 1411 - 1425. [Abstract] [Full Text] [PDF]

				R. E. Brown HER-2/neu-Positive Breast Carcinoma: Molecular Concomitants by Proteomic Analysis and their Therapeutic Implications Ann. Clin. Lab. Sci., January 1, 2002; 32(1): 12 - 21. [Abstract] [Full Text] [PDF]

				S. Saika, T. Miyamoto, T. Tanaka, I. Ishida, Y. Ohnishi, and A. Ooshima Latent TGFbeta binding protein-1 and fibrillin-1 in human capsular opacification and in cultured lens epithelial cells Br J Ophthalmol, November 1, 2001; 85(11): 1362 - 1366. [Abstract] [Full Text] [PDF]

				K.-Y. Kim, S.-Y. Jeong, J. Won, P.-D. Ryu, and M.-J. Nam Induction of Angiogenesis by Expression of Soluble Type II Transforming Growth Factor-beta Receptor in Mouse Hepatoma J. Biol. Chem., October 12, 2001; 276(42): 38781 - 38786. [Abstract] [Full Text] [PDF]

				A. Bandyopadhyay, Y. Zhu, M. L. Cibull, L. Bao, C. Chen, and L. Sun A Soluble Transforming Growth Factor {beta} Type III Receptor Suppresses Tumorigenicity and Metastasis of Human Breast Cancer MDA-MB-231 Cells Cancer Res., October 1, 1999; 59(19): 5041 - 5046. [Abstract] [Full Text] [PDF]

				D. Wang, L. Sun, E. Zborowska, J. K. V. Willson, J. Gong, J. Verraraghavan, and M. G. Brattain Control of Type II Transforming Growth Factor-beta Receptor Expression by Integrin Ligation J. Biol. Chem., April 30, 1999; 274(18): 12840 - 12847. [Abstract] [Full Text] [PDF]

				C. L. Arteaga, K. M. Koli, T. C. Dugger, and R. Clarke Reversal of Tamoxifen Resistance of Human Breast Carcinomas In Vivo by Neutralizing Antibodies to Transforming Growth Factor-ß J Natl Cancer Inst, January 6, 1999; 91(1): 46 - 53. [Abstract] [Full Text] [PDF]

				W. Chen, W. Jin, and S. M. Wahl Engagement of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4) Induces Transforming Growth Factor {beta} (TGF-{beta}) Production by Murine CD4+ T Cells J. Exp. Med., November 16, 1998; 188(10): 1849 - 1857. [Abstract] [Full Text] [PDF]

				L. Sun and C. Chen Expression of Transforming Growth Factor beta  Type III Receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells J. Biol. Chem., October 3, 1997; 272(40): 25367 - 25372. [Abstract] [Full Text] [PDF]

				C. Chen, X.-F. Wang, and L. Sun Expression of Transforming Growth Factor beta  (TGFbeta ) Type III Receptor Restores Autocrine TGFbeta 1 Activity in Human Breast Cancer MCF-7 Cells J. Biol. Chem., May 9, 1997; 272(19): 12862 - 12867. [Abstract] [Full Text] [PDF]

				K. M. Koli, T. T. Ramsey, Y. Ko, T. C. Dugger, M. G. Brattain, and C. L. Arteaga Blockade of Transforming Growth Factor-beta Signaling Does Not Abrogate Antiestrogen-induced Growth Inhibition of Human Breast Carcinoma Cells J. Biol. Chem., March 28, 1997; 272(13): 8296 - 8302. [Abstract] [Full Text] [PDF]

				K. M. Koli and C. L. Arteaga Processing of the Transforming Growth Factor beta Type I and II Receptors. BIOSYNTHESIS AND LIGAND-INDUCED REGULATION J. Biol. Chem., March 7, 1997; 272(10): 6423 - 6427. [Abstract] [Full Text] [PDF]

				J. Wang, W. Han, E. Zborowska, J. Liang, X. Wang, J. K.V. Willson, L. Sun, and M. G. Brattain Reduced Expression of Transforming Growth Factor beta Type I Receptor Contributes to the Malignancy of Human Colon Carcinoma Cells J. Biol. Chem., July 19, 1996; 271(29): 17366 - 17371. [Abstract] [Full Text] [PDF]

				V. Buchman, M Sporn, and A. Davies Role of transforming growth factor-beta isoforms in regulating the expression of nerve growth factor and neurotrophin-3 mRNA levels in embryonic cutaneous cells at different stages of development Development, January 6, 1994; 120(6): 1621 - 1629. [Abstract] [PDF]

				J. Yue and K. M. Mulder Requirement of Ras/MAPK Pathway Activation by Transforming Growth Factor beta for Transforming Growth Factor beta 1 Production in a Smad-dependent Pathway J. Biol. Chem., September 29, 2000; 275(40): 30765 - 30773. [Abstract] [Full Text] [PDF]

				D. L. Segev, T. U. Ha, T. T. Tran, M. Kenneally, P. Harkin, M. Jung, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFkappa B-mediated Pathway J. Biol. Chem., September 8, 2000; 275(37): 28371 - 28379. [Abstract] [Full Text] [PDF]

				A. Choudhury, R. K. Singh, N. Moniaux, T. H. El-Metwally, J.-P. Aubert, and S. K. Batra Retinoic Acid-dependent Transforming Growth Factor-beta 2-mediated Induction of MUC4 Mucin Expression in Human Pancreatic Tumor Cells Follows Retinoic Acid Receptor-alpha Signaling Pathway J. Biol. Chem., October 20, 2000; 275(43): 33929 - 33936. [Abstract] [Full Text] [PDF]